BGB116673 free base · Synonyms: BGB-116673 · BGB 116673

BGB‐16673 is an investigational BTK‐targeting chimeric degradation activation compound (CDAC) active against both wild‐type and mutant BTK.

For research use only. Not for human or veterinary use.

Target PROTACs Btk NF-κB

Research area Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

BGB116673 structure

CAS No.: 2736508-60-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 585.00	BP-02260-50mg	In stock	Get quote
100 mg	USD 865.00	BP-02260-100mg	In stock	Get quote
250 mg	USD 1,598.00	BP-02260-250mg	In stock	Get quote
500 mg	USD 2,865.00	BP-02260-500mg	In stock	Get quote
1 g	Inquire	BP-02260-1g	In stock	Inquire
5 g	Inquire	BP-02260-5g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

BGB‐16673 is an investigational BTK‐targeting chimeric degradation activation compound (CDAC) active against both wild‐type and mutant BTK.

Biological activity

BTK-IN-29 (compound 14) is an inhibitor of Btk.

Identifiers

SMILES: C[C@H](C1=C(C=C(C2=C3C=C(C4=CN=C(N5CCN(CC5)CC6CCN(C7=CC=C(N8CCC(NC8=O)=O)C=C7)CC6)C=C4)NC3=NC=N2)C=C1)C)NC(C9=NC(C(C)(C)C)=NO9)=O
InChIKey: ZSOLMVZWDSGPDD-SSEXGKCCSA-N

Specifications

MW (average): 851.0097
Formula: C₄₇H₅₄N₁₂O₄
CAS No.: 2736508-60-2
Physical state: Solid
Color: Light yellow to green yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

In vitro: DMSO : 125 mg/mL

Documents

References

[1]. Wang H, et al. BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models. Blood, 2024, 144: 5833.

[2]. Wu Y, et al. Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase-targeted protein degrader BGB-16673. Br J Pharmacol. 2024 Dec;181(24):4973-4987.

[3]. Hexiang Wang, et al. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use. WO2021219070A1. 2021-11-04.

Same target

Search PROTACs

Same research area

Search Inflammation/Immunology